DLC joins patients, providers and policymakers in calling on the Federal Trade Commission to investigate pharmacy benefit manager (PBM) practices contributing to higher prescription costs. Board Chair Stewart Perry wrote, "We strongly urge the FTC, as the nation’s protector of consumers and competition, to bring much needed transparency and accountability to the PBM industry so the nation can begin to repair the most dysfunctional segment of our health care system."
